Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy

This is a study of tisagenlecleucel of for high risk B-cell acute lymphoblastic leukemia in children and young adults. The goal is to find out how safe it is and how well it works. Tisagenlecleucel is a kind of medicine made up of cells (a "cell therapy"). It is made by taking immune cells called T cells (a type of white blood cell) and changing them in a lab in way that makes them able to find and destroy cancer cells.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT03876769
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 1-25 inclusive
Diagnosis of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Positive test result for CD19
MRD Positive test result at the end of consolidation treatment
Exclusion Criteria:
Treatment with any prior gene or engineered T cell therapy
Philadelphia chromosome positive (Ph+) ALL
M3 marrow at the completion of first-line induction therapy
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA